

Analyst

John Hester 612 8224 2871
Tanushree Jain 612 8224 2849

Authorisation

TS Lim 612 8224 2810

Oncosil Medical (OSL)

Commercial Validation Awaits

Speculative

See key risks on Page 5 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.

Recommendation

Buy (unchanged)

Price

\$0.11

Valuation

\$0.42 (previously \$0.38)

Risk

Speculative

GICS Sector

Healthcare Equipment and Services

Expected Return

Capital growth	282%
Dividend yield	0.0%
Total expected return	282%


Company Data & Ratios

Enterprise value	\$62.4m
Market cap	\$69.4m
Issued capital	630.7m
Free float	100%
Avg. daily val. (52wk)	\$303,000
12 month price range	\$0.05 - \$0.21

Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.09	0.18	0.05
Absolute (%)	23.7	-34.3	121.2
Rel market (%)	13.9	-13.6	133.4

Absolute Price



SOURCE: IRESS

First Revenue Likely in 2020

OSL received the CE Mark for its Oncosil therapy for the treatment of inoperable locally advanced pancreatic cancer earlier in April as anticipated. The CE Mark allows the company to commence the commercial sale of the device in the UK, Europe and numerous other countries around the world (excluding the US, Japan and China). The CE Mark follows the Breakthrough Designation with the US FDA in March 2020.

We estimate the addressable market in locally advanced pancreatic cancer as being at least A\$1.2bn with the potential for significant label expansion into other disease including primary liver cancer as well as off label use in bile duct cancer and for down staging of borderline surgical patients in pancreatic cancer. Oncosil therapy is the first significant breakthrough in the treatment of pancreatic cancer since the approval of the chemotherapy agent Abraxane in 2013.

This report reviews the survival data to emerge from the PanCo study which underpinned both the CE Mark and Breakthrough Designation.

We expect Oncosil will be launched in the UK and Europe later this calendar year in at least 12 hospitals, quickly expanding to 20. Average revenue per case is expected to exceed A\$20,000, hence once momentum builds we anticipate OSL will rapidly exceed \$10m in annual revenues. Over the next year we also expect the company to advance plans for a randomised clinical trial in the US. Based on the outcomes from the PanCo study which demonstrated a clear survival benefit, and assuming similar results are achieved in a US pivotal study, Oncosil appears destined to become the standard of care for locally advanced pancreatic cancer.

Valuation Raised to \$0.42

Based on the demonstrated survival benefit, we believe Oncosil therapy will achieve commercial validation shortly following launch. Valuation is raised to \$0.42 and we maintain our Speculative Buy recommendation.

Earnings Forecast

June Year End	FY19	FY20e	FY21e	FY22e
Revenues	3.6	3.6	6.7	13.7
EBITDA \$m	-8.7	-7.9	-16.5	-13.2
NPAT (underlying) \$m	-8.5	-7.7	-16.4	-13.1
NPAT (reported) \$m	-8.5	-7.7	-16.4	-13.1
EPS underlying (cps)	-1.4	-1.2	-2.0	-1.6
EPS growth %	nm	-9%	61%	-20%
PER (x)	nm	nm	nm	nm
FCF yield (%)	nm	nm	nm	nm
EV/EBITDA (x)	nm	nm	nm	nm
Dividend (cps)	-	-	-	-
Franking	0%	0%	0%	0%
Yield %	0.0%	0.0%	0.0%	0.0%
ROE %	-81.6%	-266.0%	-45.3%	-56.6%

SOURCE: BELL POTTER SECURITIES ESTIMATES

CE Mark Secured

Following the awarding of the CE Mark we take the opportunity to revisit the key data from the Panco study. The study dosed 42 subject with locally advanced pancreatic cancer and the key data points are outlined below.

This clinical data will be used by the company in its marketing pitch across Europe in the months ahead and it is also the data responsible for the Breakthrough Designation in the US.

The comparative data on each of the efficacy measures is extracted from an extensive literature review conducted by the company as part of CE Mark submission to the BSI¹.

Figure 1 - Oncosil therapy - key efficacy measures vs retrospective literature review data

	Oncosil + Chemotherapy (per protocol)	95% CI	Chemotherapy only	Induction Chemo and Consolidation Chemoradiotherapy	All treatments
Overall Survival (months)	16.0	11.1, NC	12.7	12.6	12.7
Progression Free Survival (months)	9.3	7.2 - 12.2	6.6	7.6	7.6
Local disease control rate (week 24)	100%	91.6 - 100	71.3%	na	88.5%
Resection rates %	23.8%	12.1 - 39.5	7.7%	na	11.5%

SOURCE: COMPANY DATA

In relation to surgical resection:

10 implanted study participants in the Panco study were restaged and subsequently had surgical resection with curative intent. Of these subjects, 8 had R0 surgical margins which indicates no detectable cancerous cells in the tissue surrounding tumour following excision.

Surgical resection in LAPC is critical, improving the 5 year survival rate from 5% to 20%.

Based on this summary data we note the following key points:

- Firstly, the state of the art therapy is defined by clinical practice guidelines as set out by the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). The NCCN guidelines in particular offer numerous options for chemotherapy regimens.
- Across all guidance, the standard for locally advanced pancreatic cancer are induction chemotherapy, chemotherapy and consolidation chemo radiotherapy.

OVERALL SURVIVAL

The gold standard for efficacy is overall survival benefit. In figure 1, overall survival in the Oncosil group was measured across 42 patients all of whom were implanted with Oncosil (being the treatment per protocol group). Relative to the standard of care the overall survival (OS) benefit is approximately 3.3 months. Even though the PanCo study was not randomised, the investigators estimate a pro-forma p-value (vs the patients in the literature review) of 0.001 which is highly statistically significant.

¹ BSI – British Standard Institute

The extension in overall survival (being approximately a 26% extension from the SOC) is an outstanding outcome and the data is still maturing. The long term survival data is yet to be published as we understand many of the patients are still alive.

Progression free survival (PFS) is a commonly used proxy for overall survival in cancer trials (before the OS data has matured). Several drugs have been awarded accelerated approval by the FDA on the basis of a meaningful extension in PFS. These approvals are typically subject confirmatory studies and an overall survival benefit. In this case the PFS data is of limited significance as the interim OS data is available.

RESECTION RATE

The resection rate is a measure of patients first classified as inoperable, who are later reclassified/down staged and become suitable for surgery (following initial treatment). Under the current standard of care (SOC), the resection rate is between 7 – 11%, relative to the Oncosil regime at ~24% (i.e. more than double SOC).

The resection rate is significant because of the survival benefit associated with the surgery. Key data from the literature review shows that patients undergoing surgical resection had significantly better survival than patients who did not. Median overall survival was 35.3 months vs 16.3 months and three year survival rates of 50% vs 11% (p<0.001).

Based on the PanCo study, the Oncosil regime appears to be a highly effective treatment for down staging inoperable tumours such that they become operable.

ADDRESSABLE MARKET

The CE Mark is for inoperable locally advanced pancreatic cancer (LAPC).

We estimate the total addressable market as follows:

Figure 2 – Total Addressable Market (TAM) Estimate

LAPC	United Kingdom	European Union	United States	Australia	TAM
Estimated Annual Incidence	8,700	79,000	48,000	3,350	
Locally Advanced Pancreatic Cancer Patients @ 40%	3,480	31,600	19,200	1,340	
Revenue per patient (local currency)	8,000	12,000	25,000	20,000	
FX Rate	0.5093	1.1505	0.637	1.00	
A\$m	55	330	754	27	1,165

SOURCE: BELL POTTER SECURITIES ESTIMATES

The calculation excludes Japan and China both of which are large markets. China for example is estimated to have more than 65,000 cases annually. Japan is also likely to require a small local trial prior to an approval. We expect the company to partner the Oncosil therapy in both jurisdictions.

Our estimated addressable market of A\$1.1bn includes only the market for locally advanced pancreatic cancer (LAPC - the form of the disease which is inoperable and has not yet spread to other organs outside of the pancreas) which represents 30-40% of all cases.

The aim with this patient group is to downstage the cancer such that the patients become eligible for surgery, hence the focus on resection rates.

The largest market segment is those with metastatic disease. Typically these patients are treated with a variety of chemotherapy regimens, however, the prognosis for them is poor. This group was excluded from the PanCo study and is also unlikely to be funded by any insurer or public body, nevertheless it is not inconceivable that self-pay patients may be willing to try off label treatment in conjunction with a regime of chemotherapy. We exclude this group from the estimate of TAM.

Other off label treatment groups are those with borderline resectable cancers as well as those with bile duct cancer (which is the subject of humanitarian device exemption) in the US.

FUNDING

Funding for Oncosil therapy will come from a variety of sources depending upon the country and the patient. Initially in Europe and the UK we expect a mix of public funding and private pay. The company is working with advisors to secure various pockets of funding from the NHS in the UK as well as regional health authorities in Europe. Further funding may be available as data from a large randomised clinical trial becomes available.

Funding for any new therapy in Europe is challenging, nevertheless the data from the literature review is so overwhelmingly one sided in favour of Oncosil therapy relative to the standard of care, we expect that patient advocacy groups and the oncology community will be strongly supportive of this therapy.

OSL is likely to conduct a health economics study to justify higher pricing in the US. Our initial forecast is for the US market is set with the price of US\$30,000. This is likely to be a conservative first estimate.

LAUNCH TIMETABLE

We expect OSL will launch Oncosil therapy later this year once the COVID19 crisis has passed and staff are able to access hospitals. In the interim the company is preparing numerous local country product registrations including for the Asia Pacific region. The CE mark is recognised in most countries except for the US, China and Japan. We expect at least a dozen hospitals initially across the UK and other key markets in Europe expanding to ~20 sites within 12 months.

The outlook for revenue generation across just 20 sites is attractive. At one to two procedures per month per site, the revenues quickly exceed A\$1m/month and growing.

OSL is currently funded for a limited launch in Europe, however, as utilisation grows the company is likely to require further working capital.

SUMMARY OF EARNINGS CHANGES

Figure 3 - Summary of earnings changes

	2020			2021			2022		
	New	Old	% change	New	Old	% change	New	Old	% change
Revenues	3.6	3.6	0.0%	6.7	6.7	1%	13.7	11.8	16%
EBITDA	-7.9	-7.9	0.6%	-16.5	-16.5	0%	-13.2	-14.8	11%
NPAT	-7.7	-7.7	-0.6%	-16.4	-16.4	0%	-13.1	-14.8	11%
EPS	-1.2	-1.2	-3.4%	-2.0	-2.0	0%	-1.6	-1.8	12%

SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES

First meaningful revenues from product sales are due in FY21. Valuation is modestly upgraded from \$0.38 to \$0.42 and we maintain our speculative Buy recommendation.

Oncosil Limited

Oncosil Limited is a single product medical device company. Oncosil is a first in class intratumoral brachytherapy device seeking approval for the treatment of inoperable pancreatic cancer.

The initial target market for OncoSil™ is in pancreatic cancer where there remains a high unmet clinical need. It is estimated that each year there are more than new 87,000 cases in Europe and 48,000 new cases in the US. Five year survival is less than 1 in 20. The company also has aspirations to develop Oncosil for Primary Liver Cancer.

The company completed the PanCo study in 2019 and is received the CE Mark to treat inoperable locally advance pancreatic cancer in April 2020. The US FDA granted an Investigational Device Exemption (IDE) in August 2016 and awarded Breakthrough designation in March 2020. The trial design for a US approval study is yet to be discussed with the FDA. The company will be required to conduct at least 1 large pivotal study in the US in order to gain approval.

KEY RISKS

Emerging therapy – Medical science continues to evolve and new therapies are constantly emerging. The oncology field attracts more R&D investment than most and consequently there are many new drugs in the pipeline. Despite this, based on our enquiries there are no late stage drugs in development for the treatment of Pancreatic Cancer. Clinical trials frequently produce good result at the phase II stage of development, however, these often fail to repeat in broader populations across multiple treatment centres. While the threat of an emerging therapy is constant, it is not imminent.

Medical Community is slow to adopt new therapy – Especially where the treatment is not supported by evidence from a large randomised controlled study. Consequently, our assumptions relating to adoption rates may overestimate potential revenues. Oncosil faces the additional challenge that it is the first brachytherapy for the treatment of pancreatic cancer.

Funding – Oncosil is likely to required further equity in order to complete the clinical program.

Clinical Risk – OSL has an investigational device exemption in the US for pancreatic cancer. Success in the clinic is required in order for the product to be marketed in the US. There is no guarantee that results from previous studies will be repeated in a broader, multi centre trial.

Other commercial risks - The validity of patents which protect the future income stream from OncoSil are yet to be tested. In addition, normal commercial risk relating to reliance on suppliers also apply. Oncosil Medical Ltd does not manufacture the Oncosil product and is entirely depended on a small number of hi-tech manufacturers for supply to its customer base. OncoSil is a highly toxic material. Its manufacture, storage, transport and use are each subject to regulatory requirements. OncoSil relies on various external parties to manage these risks in the normal course of their business.

Table 1 - Financial summary

Profit & Loss (A\$m)	FY18	FY19	FY20e	FY21e	FY22e
Year Ending June					
Dose sales (units)	-	-	-	205	490
Net revenue from product sales	-	-	0.6	3.7	8.7
COGS	-	-	0.1	-0.7	-1.7
Gross profit	-	-	0.5	3.0	6.9
GP margin				80%	80%
R&D incentive/Upfront receipts	4.4	3.6	3.0	3.0	5.0
Total revenues	4.4	3.6	3.6	6.7	13.7
Other expenses	-5.8	-5.6	-4.0	-10.0	-12.0
Other expenses	-13.1	-6.7	-7.3	-12.5	-13.2
EBITDA	-8.7	-8.7	-7.9	-16.5	-13.2
Depreciation	0.0	0.0	0.0	0.0	0.0
Amortisation	0.0	0.0	0.0	0.0	0.0
EBIT	-8.7	-8.7	-7.8	-16.5	-13.2
Sundry income	0.2	0.2	0.1	0.1	0.1
Pre tax profit	-8.6	-8.5	-7.7	-16.4	-13.1
Tax expense	-	-	-	-	-
NPAT - normalised	-8.6	-8.5	-7.7	-16.4	-13.1
Net abnormal items	-	-	-	-	-
Reported NPAT	-8.6	-8.5	-7.7	-16.4	-13.1
Cashflow (A\$m)	FY18	FY19	FY20e	FY21e	FY22e
Gross cashflow	-8.5	-7.7	-7.0	-13.9	-13.7
Net interest	0.1	0.2	0.1	0.1	0.1
Tax paid	0.0	0.0	0.0	0.0	0.0
Operating cash flow	-8.4	-7.5	-6.9	-13.8	-13.6
Maintenance capex	0.0	0.0	0.0	0.0	0.0
Capitalised clinical trial spend	0.0	0.0	0.0	0.0	0.0
Free cash flow	-8.4	-7.5	-6.9	-13.8	-13.7
Business acquisitions	0.0	0.0	0.0	0.0	0.0
Proceeds from issuance	15.6	0.0	0.0	50.0	0.0
Movement in investments	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0
Change in cash held	7.1	(7.5)	(6.9)	36.2	(13.7)
Cash at beginning of period	8.0	15.2	7.7	0.7	36.9
Cash at year end	15.2	7.7	0.7	36.9	23.2
Balance Sheet (A\$m)	FY18	FY19	FY20e	FY21e	FY22e
Cash	15.2	7.7	0.7	36.9	23.2
Receivables	4.5	3.8	3.0	0.4	0.9
Short term investments	-	-	-	-	-
Other current assets	0.1	0.1	0.1	0.1	0.1
Property, Plant and Equipment	0.1	0.1	0.1	0.1	0.2
Total assets	19.9	11.7	4.0	37.5	24.4
Trade payables	1.6	0.8	0.8	0.8	0.8
Other provisions	0.1	0.2	0.2	0.2	0.3
Total Liabilities	1.7	1.0	1.0	1.0	1.0
Net Assets	18.2	10.7	3.0	36.5	23.4
Share capital	52.3	52.3	52.3	102.3	102.3
Retained earnings	(39.1)	(47.6)	(55.3)	(71.8)	(84.9)
Reserves	5.0	6.0	6.0	6.0	6.0
Shareholders Equity	18.2	10.7	2.9	36.5	23.4

Last sale 17/04/2020	0.110
Recommendation	Buy (Spec)
Issued Capital	630.7
Market Cap	69.4

Valuation Ratios (A\$m)	FY18	FY19	FY20e	FY21e	FY22e
Reported EPS (cps)	-1.7	-1.4	-1.2	-2.0	-1.6
Normalised EPS (cps)	-1.7	-1.4	-1.2	-2.0	-1.6
EPS growth (%)	-11%	nm	-9%	61%	-0.2
PE(x)	nm	nm	nm	nm	nm
EV/EBITDA (x)	-7.2	nm	nm	nm	nm
EV/EBIT (x)	-7.2	nm	nm	nm	nm
NTA (cps)	2.9	1.7	0.5	4.4	2.8
P/NTA (x)	0.0	0.1	0.2	0.0	0.0
Book Value (cps)	2.9	1.7	0.5	4.4	2.8
Price/Book (x)	0.0	0.1	0.2	0.0	0.0
DPS (cps)	-	-	-	-	-
Payout ratio %	0%	0%	0%	0%	0%
Dividend Yield %	0.0%	0.0%	0.0%	0.0%	0.0%
Franking %	150%	0%	0%	0%	0%
FCF yield %	-1230%	-1099%	-1008%	-1527%	-1510%

Net debt/Equity	0%	0%	0%	0%	0%
Net debt/Assets	0%	0%	0%	0%	0%
Gearing	net cash	net cash	net cash	net cash	net cash
Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
Interest cover (x)	n/a	n/a	n/a	n/a	n/a

Dose sales (Units)	FY20e	FY21e	FY22e
Europe	-	175	400
USA	-	-	-
Australia/Asia Pacific	-	30	90
Total dose sales	-	205	490

SOURCE: BELL POTTER SECURITIES ESTIMATES

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
Industrials			
Steven Anastasiou	Industrials	613 9235 1952	sanastasiou
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Damien Williamson	Industrials	613 9235 1958	dwilliamson
Healthcare/Biotech			
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
Financials			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified Financials/Fintech	613 9235 1668	Isotiriou
Resources			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
Associate			
jJoseph House	Associate Analyst	+61 3 9235 1624	jhouse

Bell Potter Securities Limited
ACN 25 006 390 7721
Level 29, 101 Collins Street
Melbourne, Victoria, 3000
Telephone +61 3 9256 8700
www.bellpotter.com.au

Bell Potter Securities (HK) Limited
Room 1701, 17/F
Posperity Tower, 39 Queens Road
Central, Hong Kong, 0000
Telephone +852 3750 8400

Bell Potter Securities (US) LLC
Floor 39
444 Madison Avenue, New York
NY 10022, U.S.A
Telephone +1 917 819 1410

Bell Potter Securities (UK) Limited
16 Berkeley Street
London, England
W1J 8DZ, United Kingdom
Telephone +44 7734 2929

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Research Policies: For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://www.bellpotter.com.au/topnavigation/private-clients/stockbroking/research>

Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

Biotechnology Risk Warning:

The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock.

ANALYST CERTIFICATION: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.